REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C - Candlesense
AMGN Regulatory

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to...

Related Questions

How will the expanded indication for Repatha affect Amgen's revenue forecasts and earnings guidance? What is the expected impact of the broader FDA approval on Repatha's market share versus competing PCSK9 inhibitors and statins? Will the new indication lead to changes in pricing, reimbursement, or insurance coverage that could influence the drug's adoption rate?
Find similar articles on Candlesense prnewswire